 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
19 September 2000 | Volume 133 Issue 6 | Pages 464-470
Placebo controls are commonly used in clinical trials of investigational treatments because they have important advantages. In recent years, some have criticized the use of placebo-controlled trials when effective alternative therapy exists, regardless of the expected effect of the therapy. In part 1 of this paper, ethical arguments are addressed and the interpretive problems inherent in the use of active-control equivalence trials to establish efficacy of a new treatment are clarified. However, uncertainties may complicate decisions about appropriate use of placebo controls in some situations. Part 2 discusses more fully the ethical considerations for using placebo controls in particular medical settings. The value and relevance of placebo-controlled trials of new agents in situations in which proven effective therapy is available are also explored.
Author and Article Information
From the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland.
Acknowledgments: The authors thank Drs. Jay Siegel, Marc Walton, Janet Wittes, William Schwieterman, and Mary Foulkes for helpful comments on earlier versions of this manuscript.
Requests for Single Reprints: Susan Ellenberg, PhD, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852.
Current Author Addresses: Dr. Ellenberg: Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852.
Dr. Temple: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 5600 Fishers Lane, HFD-101/WOC II—6014, Rockville, MD 20857. MEDICINE AND PUBLIC ISSUES
Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Gomberg-Maitland Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials Proceedings of the ATS, July 15, 2008; 5(5): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malozowski Comparative Efficacy: What We Know, What We Need to Know, and How We Can Get There Ann Intern Med, May 6, 2008; 148(9): 702 - 703. [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Greenspan, H. G. Bone, M. P. Ettinger, D. A. Hanley, R. Lindsay, J. R. Zanchetta, C. M. Blosch, A. L. Mathisen, S. A. Morris, T. B. Marriott, et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial Ann Intern Med, March 6, 2007; 146(5): 326 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul and G. A. Diamond Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials Ann Intern Med, July 4, 2006; 145(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R M Kaplan, B Spring, and K Davidson APA, NAMI, NMHA, and evidence-based behavioural medicine: a comment. Evid. Based Ment. Health, May 1, 2006; 9(2): 32 - 34. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Bola Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm? Schizophr Bull, April 1, 2006; 32(2): 288 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Nagasako and D. A. Kalauokalani Ethical aspects of placebo groups in pain trials: Lessons from psychiatry Neurology, December 29, 2005; 65(12_suppl_4): S59 - S65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis Arch Gen Psychiatry, December 1, 2005; 62(12): 1305 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Woods, R. V. Gueorguieva, C. B. Baker, and R. W. Makuch Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia Arch Gen Psychiatry, September 1, 2005; 62(9): 961 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden and R. Temple The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process Circulation, April 5, 2005; 111(13): 1697 - 1702. [Full Text] [PDF]
|
|
|
|
 |
|
 R.B. D'Agostino Sr. and J.M. Massaro New Developments in Medical Clinical Trials J. Dent. Res., July 1, 2004; 83(suppl_1): C18 - C24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Strand, S. Cohen, B. Crawford, J. S. Smolen, and D. L. Scott Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis Rheumatology, May 1, 2004; 43(5): 640 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R E Ashcroft Current epistemological problems in evidence based medicine J. Med. Ethics, April 1, 2004; 30(2): 131 - 135. [Abstract] [Full Text]
|
|
|
|
|
|
R K Lie, E Emanuel, C Grady, and D Wendler The standard of care debate: the Declaration of Helsinki versus the international consensus opinion J. Med. Ethics, April 1, 2004; 30(2): 190 - 193. [Abstract] [Full Text]
|
|
|
|
|
|
W. W. Fleischhacker, P. Czobor, M. Hummer, G. Kemmler, R. Kohnen, and J. Volavka Placebo or Active Control Trials of Antipsychotic Drugs? Arch Gen Psychiatry, May 1, 2003; 60(5): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Black, W. J. Elliott, G. Grandits, P. Grambsch, T. Lucente, W. B. White, J. D. Neaton, R. H. Grimm Jr, L. Hansson, Y. Lacourciere, et al. Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial JAMA, April 23, 2003; 289(16): 2073 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Temple and R. Meyer Continued Need for Placebo in Many Cases, Even When There Is Effective Therapy Arch Intern Med, February 10, 2003; 163(3): 371 - 371. [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Carpenter Jr., P. S. Appelbaum, and R. J. Levine The Declaration of Helsinki and Clinical Trials: A Focus on Placebo-Controlled Trials in Schizophrenia Am J Psychiatry, February 1, 2003; 160(2): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.G. Gilliam, F. Veloso, M.A.M. Bomhof, S.K. Gazda, V. Biton, J.P. Ter Bruggen, W. Neto, C. Bailey, G. Pledger, and S.-C. Wu A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy Neurology, January 28, 2003; 60(2): 196 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The PREVENT Investigator Group Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the Prospective Evaluation of Dalteparin efficacy for Prevention of Venous Thromboembolism in Immobilized Patients Trial (the PREVENT study) Vascular Medicine, November 1, 2002; 7(4): 269 - 273. [Abstract] [PDF]
|
|
|
|
|
|
F. G. Miller and A. F. Shorr Unnecessary Use of Placebo Controls: The Case of Asthma Clinical Trials Arch Intern Med, August 12, 2002; 162(15): 1673 - 1677. [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Miller and A. F. Shorr Ethical Assessment of Industry-Sponsored Clinical Trials* : A Case Analysis Chest, April 1, 2002; 121(4): 1337 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Emanuel and F. G. Miller The Ethics of Placebo-Controlled Trials -- A Middle Ground N. Engl. J. Med., September 20, 2001; 345(12): 915 - 919. [Full Text] [PDF]
|
|
|
|
|
|
B. Djulbegovic Placebo-Controlled Trials Ann Intern Med, July 3, 2001; 135(1): 62 - 63. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Throckmorton Future Trials of Antiplatelet Agents in Cardiac Ischemia N. Engl. J. Med., June 21, 2001; 344(25): 1937 - 1939. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman Clinical Trials in Cardiovascular Medicine Circulation, May 29, 2001; 103 (21): e101 - e104. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Orentlicher Placebo-Controlled Trials of New Drugs: Ethical Considerations Diabetes Care, April 1, 2001; 24(4): 771 - 772. [Full Text]
|
|
|
|
|
|
B. Djulbegovic and M. Clarke Scientific and Ethical Issues in Equivalence Trials JAMA, March 7, 2001; 285(9): 1206 - 1208. [Full Text] [PDF]
|
|
|
|
 |
|
 R J Lilford, B. Djulbegovic, U. Schuklenk, K. J Rothman, and K. B Michels Declaration of Helsinki should be strengthened BMJ, February 3, 2001; 322(7281): 299a - 299. [Full Text]
|
|
|
|
|
|
R. Temple and S. S. Ellenberg Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues Ann Intern Med, September 19, 2000; 133(6): 455 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Simon Are Placebo-Controlled Clinical Trials Ethical or Needed When Alternative Treatment Exists? Ann Intern Med, September 19, 2000; 133(6): 474 - 475. [Full Text] [PDF]
|
|
Article
